Recurrence, Reoperation, Pregnancy Rates, and Risk Factors for Recurrence after Ovarian Endometrioma Surgery: Long-Term Follow-Up of 756 Women
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aims of this study were to evaluate the cumulative recurrence, reoperation, and pregnancy rates after ovarian endo metrioma surgery at a single institution for more than a 5-year follow-up period. Materials and Methods: This study was conducted as a retrospective chart review of patients with ovarian endometrioma who underwent surgery between January 2008 and March 2016. Study subjects included premenopausal women with at least 5 years of follow-up. Exclusion criteria were patients with stage I or II ovarian endometrioma, those who underwent hysterectomy or bi lateral oophorectomy, and presence of residual ovarian lesions on the first postoperative ultrasonography at 3–6 months. Recur rence was defined as a cystic mass by ultrasonography. Results: A total of 756 patients were recruited. The median follow-up duration was 85.5 months (interquartile range, 71–107 months). Recurrent endometrioma was detected in 27.9% patients, and reoperation was performed in 8.3% patients. Cumulative rates at 24, 36, 60, and 120 months were 5.8%, 8.7%, 15.5% and 37.6%, respectively, for recurrence and 0.1%, 0.5%, 2.9%, and 15.1%, respectively, for reoperation. After multivariable analysis, age ≤31 years [hazard ratio (HR)=2.108; 95% confidence interval (CI)=1.522–2.921; p<0.001], no subsequent pregnancy (HR=1.851; 95% CI=1.309–2.617; p<0.001), and postoperative hormonal treatment ≤15 months (HR=2.869; 95% CI=2.088–3.941; p<0.001) were significant risk factors for recurrent endometrioma. Among 315 patients who desired pregnancy, 54.0% were able to have a successful pregnancy and delivery. Conclusion: Considering that longer postoperative hormonal treatment is the sole modifiable factor for recurrent endometrio ma, we recommend long-term hormonal treatment until subsequent pregnancy, especially in younger women.
Abstract
Purpose: The aims of this study were to evaluate the cumulative recurrence, reoperation, and pregnancy rates after ovarian endo metrioma surgery at a single institution for more than a 5-year follow-up period. Materials and Methods: This study was conducted as a retrospective chart review of patients with ovarian endometrioma who underwent surgery between January 2008 and March 2016. Study subjects included premenopausal women with at least 5 years of follow-up. Exclusion criteria were patients with stage I or II ovarian endometrioma, those who underwent hysterectomy or bi lateral oophorectomy, and presence of residual ovarian lesions on the first postoperative ultrasonography at 3–6 months. Recur rence was defined as a cystic mass by ultrasonography. Results: A total of 756 patients were recruited. The median follow-up duration was 85.5 months (interquartile range, 71–107 months). Recurrent endometrioma was detected in 27.9% patients, and reoperation was performed in 8.3% patients. Cumulative rates at 24, 36, 60, and 120 months were 5.8%, 8.7%, 15.5% and 37.6%, respectively, for recurrence and 0.1%, 0.5%, 2.9%, and 15.1%, respectively, for reoperation. After multivariable analysis, age ≤31 years [hazard ratio (HR)=2.108; 95% confidence interval (CI)=1.522–2.921; p<0.001], no subsequent pregnancy (HR=1.851; 95% CI=1.309–2.617; p<0.001), and postoperative hormonal treatment ≤15 months (HR=2.869; 95% CI=2.088–3.941; p<0.001) were significant risk factors for recurrent endometrioma. Among 315 patients who desired pregnancy, 54.0% were able to have a successful pregnancy and delivery. Conclusion: Considering that longer postoperative hormonal treatment is the sole modifiable factor for recurrent endometrio ma, we recommend long-term hormonal treatment until subsequent pregnancy, especially in younger women.
참고문헌 (35)
- Eskenazi B, "Epidemiology of endometriosis", Obstet Gynecol Clin North Am, 24, pp.235~258 (1997)
- Bulun SE, "Endometriosis", N Engl J Med, 360, pp.268~279 (2009)
- Meuleman C, "High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners", Fertil Steril, 92, pp.68~74 (2009)
- Hart RJ, "Excisional surgery versus ablative surgery for ovarian endometriomata", Cochrane Database Syst Rev, 2, pp.CD004992~ (2008)
- Somigliana E, "Risks of conservative management in women with ovarian endometriomas undergoing IVF", Hum Reprod Update, 21, pp.486~499 (2015)
- Jadoul P, "Surgical treatment of ovarian endometriomas : state of the art?", Fertil Steril, 98, pp.556~563 (2012)
- Guo SW, "Recurrence of endometriosis and its control", Hum Reprod Update, 15, pp.441~461 (2009)
- Shakiba K, "Surgical treatment of endometriosis : a 7-year follow-up on the requirement for further surgery", Obstet Gynecol, 111, pp.1285~1292 (2008)
- Kim ML, "Recurrence of ovarian endometrioma after second-line, conservative, laparoscopic cyst enucleation", Am J Obstet Gynecol, 210, pp.216~ (2014)
- Busacca M, "Endometrioma excision and ovarian reserve : a dangerous relation", J Minim Invasive Gynecol, 16, pp.142~148 (2009)
- Donnez J, "Surgical management of endometriosis", Best Pract Res Clin Obstet Gynaecol, 18, pp.329~348 (2004)
- Kikuchi I, "Recurrence rate of endometriomas following a laparoscopic cystectomy", Acta Obstet Gynecol Scand, 85, pp.1120~1124 (2006)
- Koga K, "Recurrence of ovarian endometrioma after laparoscopic excision", Hum Reprod, 21, pp.2171~2174 (2006)
- Vercellini P, "Postoperative oral contraceptive exposure and risk of endometrioma recurrence", Am J Obstet Gynecol, 198, pp.504~ (2008)
- Seong SJ, "Role of hormone therapy after primary surgery for endometrioma : a multicenter retrospective cohort study", Reprod Sci, 23, pp.1011~1018 (2016)
- Lee DY, "Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence", Hum Reprod, 25, pp.3050~3054 (2010)
- Vercellini P, "Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence : a systematic review and meta-analysis", Acta Obstet Gynecol Scand, 92, pp.8~16 (2013)
- Seo JW, "Comparison of longterm use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery", Eur J Obstet Gynecol Reprod Biol, 236, pp.53~57 (2019)
- Cho S, "Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence", Acta Obstet Gynecol Scand, 93, pp.38~44 (2014)
- Loverro G, "A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis", Eur J Obstet Gynecol Reprod Biol, 136, pp.194~198 (2008)
- Zhu SY, "Preventive therapeutic options for postoperative recurrence of ovarian endometrioma : gonadotropin-releasing hormone agonist with or without levonorgestrel intrauterine system insertion", Arch Gynecol Obstet, 303, pp.533~539 (2021)
- Li XY, "Risk factors for postoperative recurrence of ovarian endometriosis : longterm follow-up of 358 women", J Ovarian Res, 12, pp.79~ (2019)
- Mais V, "The efficiency of transvaginal ultrasonography in the diagnosis of endometrioma", Fertil Steril, 60, pp.776~780 (1993)
- Bougie O, "Longterm follow-up of endometriosis surgery in Ontario : a populationbased cohort study", Am J Obstet Gynecol, 225, pp.270~ (2021)
- Dunselman GA, "ESHRE guideline : management of women with endometriosis", Hum Reprod, 29, pp.400~412 (2014)
- Del Forno S, "Long-term medical therapy after laparoscopic excision of ovarian endometriomas : can we reduce and predict the risk of recurrence?", Gynecol Obstet Invest, 86, pp.170~176 (2021)
- Wattanayingcharoenchai R, "Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy : a systematic review and network meta-analysis", BJOG, 128, pp.25~35 (2021)
- Zakhari A, "Endometriosis recurrence following post-operative hormonal suppression : a systematic review and meta-analysis", Hum Reprod Update, 27, pp.96~107 (2021)
- Vignali M, "Effect of dienogest therapy on the size of the endometrioma", Gynecol Endocrinol, 36, pp.723~727 (2020)
- Uludag SZ, "Dienogest reduces endometrioma volume and endometriosis-related pain symptoms", J Obstet Gynaecol, 41, pp.1246~1251 (2021)
- Angioni S, "Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study", Gynecol Endocrinol, 36, pp.84~86 (2020)
- Piacenti I, "Dienogest versus continuous oral levonorgestrel", EE in patients with endometriosis : what’s the best choice?, 2021, pp.37, 471~475
- Mariani LL, "Estradiol", nomegestrol acetate as a first-line and rescue therapy for the treatment of ovarian and deep infiltrating endometriosis, 2021, pp.37, 646~649
- Capezzuoli T, "Long-term hormonal treatment reduces repetitive surgery for endometriosis recurrence", Reprod Biomed Online, 42, pp.451~456 (2021)
- Lee JH, "Effectiveness of dienogest for treatment of recurrent endometriosis : multicenter data", Reprod Sci, 25, pp.1515~1522 (2018)